Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth M Jaffee

Showing results (91-100 of 291) with videos related to

Pageof 30
Sort By:
JCI Insight|December 20, 2019
Multipanel mass cytometry reveals anti-PD-1 therapy-mediated B and T cell compartment remodeling in tumor-draining lymph nodesWon Jin Ho, Mark Yarchoan, Soren Charmsaz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 12, 2003
Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic miceAnne M Ercolini, Jean-Pascal H Machiels, Yi Cheng Chen, et al.
Cancer Immunology Research|August 14, 2021
Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist TherapyLauren Dennison, Amanda Ruggieri, Aditya Mohan, et al.
Plos One|February 24, 2012
Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cellsVivian L Weiss, Timothy H Lee, Hong Song, et al.
Journal for Immunotherapy of Cancer|November 15, 2018
Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancerMay Tun Saung, Stephen Muth, Ding Ding, et al.
Vaccine|August 7, 2007
Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type miceTimothy P Moran, Joseph E Burgents, Brian Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2020
Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression AnalysisArsen Osipov, Su Jin Lim, Aleksandra Popovic, et al.
ACS Applied Materials & Interfaces|February 2, 2019
Human Cancer Cell Membrane-Coated Biomimetic Nanoparticles Reduce Fibroblast-Mediated Invasion and Metastasis and Induce T-CellsJiefu Jin, Balaji Krishnamachary, James D Barnett, et al.
Genome Medicine|August 11, 2021
Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumorsEmily F Davis-Marcisak, Allison A Fitzgerald, Michael D Kessler, et al.
Journal of Visualized Experiments : Jove|January 19, 2013
Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissueElaine Bigelow, Katherine M Bever, Haiying Xu, et al.
Pageof 30

Showing results (91-100 of 291) with videos related to

Sort By:
Pageof 30
JCI Insight|December 20, 2019
Multipanel mass cytometry reveals anti-PD-1 therapy-mediated B and T cell compartment remodeling in tumor-draining lymph nodesWon Jin Ho, Mark Yarchoan, Soren Charmsaz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 12, 2003
Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic miceAnne M Ercolini, Jean-Pascal H Machiels, Yi Cheng Chen, et al.
Cancer Immunology Research|August 14, 2021
Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist TherapyLauren Dennison, Amanda Ruggieri, Aditya Mohan, et al.
Plos One|February 24, 2012
Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cellsVivian L Weiss, Timothy H Lee, Hong Song, et al.
Journal for Immunotherapy of Cancer|November 15, 2018
Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancerMay Tun Saung, Stephen Muth, Ding Ding, et al.
Vaccine|August 7, 2007
Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type miceTimothy P Moran, Joseph E Burgents, Brian Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2020
Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression AnalysisArsen Osipov, Su Jin Lim, Aleksandra Popovic, et al.
ACS Applied Materials & Interfaces|February 2, 2019
Human Cancer Cell Membrane-Coated Biomimetic Nanoparticles Reduce Fibroblast-Mediated Invasion and Metastasis and Induce T-CellsJiefu Jin, Balaji Krishnamachary, James D Barnett, et al.
Genome Medicine|August 11, 2021
Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumorsEmily F Davis-Marcisak, Allison A Fitzgerald, Michael D Kessler, et al.
Journal of Visualized Experiments : Jove|January 19, 2013
Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissueElaine Bigelow, Katherine M Bever, Haiying Xu, et al.
Pageof 30